SECTOR GAMMA AS
13F Reported Value
ⓘ$461.0M
Holdings
40
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
SECTOR GAMMA AS disclosed 40 positions worth $461.0M in its Form 13F-HR for Q2 2026, led by $BMY (BRISTOL MYERS SQUIBB CO) at 9.1% of the equity portfolio, followed by $MRK and $MDT. During the quarter the fund opened 6 new positions and exited 8 — including a new stake in $TMO and a full exit from $UNH. The portfolio is most concentrated in Healthcare (88.2% of disclosed assets). All figures are sourced directly from SECTOR GAMMA AS’s Form 13F-HR filing with the SEC under CIK 1475373.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 70.4#219
Quality
$41.8M726,115 sh - 59.9#898
Quality
$27.9M217,008 sh - 68.7#272
Quality
$27.6M352,437 sh - 62.0
Quality
$24.2M1,004,215 sh - 77.4
Quality
$19.4M170,753 sh - 59.0
Quality
$17.2M44,499 sh - 58.2
Quality
$16.9M294,918 sh - 65.1
Quality
$16.8M33,584 sh - 59.4
Quality
$16.1M155,337 sh - 61.4
Quality
$15.1M77,944 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BRISTOL MYERS SQUIBB CO$BMY | 70.4#219 | $41.8M | 726,115 |
 Merck & Co., Inc.$MRK | 59.9#898 | $27.9M | 217,008 |
 Medtronic plc$MDT | 68.7#272 | $27.6M | 352,437 |
 PFIZER INC$PFE | 62.0 | $24.2M | 1,004,215 |
 INCYTE CORP$INCY | 77.4 | $19.4M | 170,753 |
 Elevance Health, Inc.$ELV | 59.0 | $17.2M | 44,499 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2 | $16.9M | 294,918 |
 THERMO FISHER SCIENTIFIC INC.$TMO | 65.1 | $16.8M | 33,584 |
 CVS HEALTH Corp$CVS | 59.4 | $16.1M | 155,337 |
 IQVIA HOLDINGS INC.$IQV | 61.4 | $15.1M | 77,944 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SECTOR GAMMA AS's 40 positions.
Showing top 10 of 40 holdings.
Sector Allocation
Healthcare
$406.5M
Technology
$44.8M
Consumer Staples
$9.7M
Full Holdings — SECTOR GAMMA AS (Q2 2026)
All 40 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BMY | BRISTOL MYERS SQUIBB CO | $41.8M | 9.1% | -12% | 70.4 |
| 2 | $MRK | Merck & Co., Inc. | $27.9M | 6.0% | -17% | 59.9 |
| 3 | $MDT | Medtronic plc | $27.6M | 6.0% | +26% | 68.7 |
| 4 | $PFE | PFIZER INC | $24.2M | 5.3% | -8% | 62 |
| 5 | $INCY | INCYTE CORP | $19.4M | 4.2% | -15% | 77.4 |
| 6 | $ELV | Elevance Health, Inc. | $17.2M | 3.7% | +1% | 59 |
| 7 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $16.9M | 3.7% | +23% | 58.2 |
| 8 | $TMO | THERMO FISHER SCIENTIFIC INC. | $16.8M | 3.6% | NEW | 65.1 |
| 9 | $CVS | CVS HEALTH Corp | $16.1M | 3.5% | +15% | 59.4 |
| 10 | $IQV | IQVIA HOLDINGS INC. | $15.1M | 3.3% | +94% | 61.4 |
| 11 |  $IONS | IONIS PHARMACEUTICALS INC | $15.0M | 3.3% | +12% | 23.4 |
| 12 |  $BDX | BECTON DICKINSON & CO | $14.1M | 3.1% | +13% | 59 |
| 13 |  $ABT | ABBOTT LABORATORIES | $13.4M | 2.9% | +68% | 65.5 |
| 14 |  $GEHC | GE HealthCare Technologies Inc. | $13.3M | 2.9% | +64% | 55.7 |
| 15 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $12.3M | 2.7% | -9% | 65.7 |
| 16 |  $BIIB | BIOGEN INC. | $11.7M | 2.5% | -40% | 64.7 |
| 17 |  $QGEN | QIAGEN N.V. | $11.2M | 2.4% | +77% | — |
| 18 |  $CNC | CENTENE CORP | $10.4M | 2.3% | +0% | 58.2 |
| 19 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $9.8M | 2.1% | NEW | 71 |
| 20 |  $BIO | BIO-RAD LABORATORIES, INC. | $9.8M | 2.1% | +40% | 48.9 |
| 21 |  $CAH | CARDINAL HEALTH INC | $9.7M | 2.1% | -26% | 62.4 |
| 22 |  $AMGN | AMGEN INC | $9.5M | 2.1% | -44% | 79.2 |
| 23 |  $BRKR | BRUKER CORP | $9.2M | 2.0% | -40% | 50.8 |
| 24 |  $AVTR | Avantor, Inc. | $9.0M | 1.9% | +30% | 39.6 |
| 25 |  $PTCT | PTC THERAPEUTICS, INC. | $8.2M | 1.8% | +33% | 35.4 |
| 26 |  $LH | LABCORP HOLDINGS INC. | $7.3M | 1.6% | +37% | 65 |
| 27 |  $DXCM | DEXCOM INC | $6.9M | 1.5% | +82% | 76 |
| 28 |  $ASND | Ascendis Pharma A/S | $5.7M | 1.2% | +0% | 44.8 |
| 29 |  $EW | Edwards Lifesciences Corp | $5.5M | 1.2% | +0% | 69.4 |
| 30 |  $SNDX | Syndax Pharmaceuticals Inc | $5.3M | 1.1% | -15% | 33.8 |
| 31 |  $BSX | BOSTON SCIENTIFIC CORP | $5.2M | 1.1% | NEW | 77.5 |
| 32 |  $KURA | Kura Oncology, Inc. | $4.8M | 1.0% | +5% | 27.6 |
| 33 |  $TVTX | Travere Therapeutics, Inc. | $4.5M | 1.0% | NEW | 56.6 |
| 34 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $4.3M | 0.9% | +22% | 25.5 |
| 35 |  $TNDM | TANDEM DIABETES CARE INC | $4.0M | 0.9% | +0% | 42.8 |
| 36 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $4.0M | 0.9% | +8% | 36.8 |
| 37 |  $CYTK | CYTOKINETICS INC | $3.8M | 0.8% | NEW | 28.1 |
| 38 |  $OGN | Organon & Co. | $3.7M | 0.8% | -28% | 50.5 |
| 39 |  $ARDX | ARDELYX, INC. | $3.5M | 0.8% | +33% | 41.9 |
| 40 |  $NTLA | Intellia Therapeutics, Inc. | $3.1M | 0.7% | NEW | 19.9 |
New Positions (6)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SECTOR GAMMA AS including:
Track SECTOR GAMMA AS's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SECTOR GAMMA AS and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SECTOR GAMMA AS
13F Pro is an AI hedge fund tracker and stock research platform. For SECTOR GAMMA AS (SEC CIK: 1475373), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SECTOR GAMMA AS's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.